Dianthus Therapeutics Announces DNTH312, a First-In-Class, Next-Generation Bifunctional Fusion Protein Combining Claseprubart and TACI, for Severe Autoimmune Diseases
Dianthus Therapeutics announced DNTH312, an internally developed first-in-class bifunctional fusion protein combining claseprubart and TACI to potently inhibit aC1s and BAFF/APRIL pathways. DNTH312 demonstrates comparable potency and half-life to claseprubart and aims to be Phase 1 ready by the end of 2027. This innovative therapy targets severe au…